drugset / Trial / NCT06388564

A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

NCT06388564

Phase 2 Active not recruiting 130 enrolled Incyte Corporation
RandomizedParallel-groupOpen-labelTreatment

Summary

This study will be conducted to determine the preliminary efficacy of axatilimab in combination with ruxolitinib and to assess the contribution of axatilimab to the combination treatment effect in participants with cGVHD.

Timeline

Start
2024-10-11
Primary completion
2027-06-01
Completion
2029-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Axatilimab Monoclonal antibody
Subject Methylprednisolone Other / unclassified
Subject Prednisolone Other / unclassified
Subject Prednisone Other / unclassified
Subject Ruxolitinib Small molecule